CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Leap
Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused
on developing targeted and immuno-oncology therapeutics, today
announced that it will host a conference call on August 6, 2019, to provide a program update for
DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1
(DKK1) protein, a Wnt pathway
modulator. DKN-01 is in clinical trials in patients with
esophagogastric, hepatobiliary, gynecologic, and prostate
cancers.
Conference Call Details
Leap management will be joined by the following DKN-01 clinical
investigators:
- Samuel J. Klempner, M.D.,
Assistant Professor, Tucker Gosnell Center for Gastrointestinal
Cancers, Massachusetts General Hospital Cancer Center and
Harvard Medical School
- Rebecca C. Arend, M.D.,
Assistant Professor and Associate Scientist, Gynecologic Oncology
Clinic, UAB Comprehensive Cancer Center Experimental Therapeutics
Program
U.S. Dial-in Number: (866) 589-0108
International Dial-in Number: (409) 231-2048
Conference ID: 3571417
The slides and audio webcast can also be accessed by visiting
the Investors section of the Company's website at
http://www.leaptx.com. A replay of the webcast will be available
shortly after the conclusion of the call and will be archived on
the Company's website for 30 days.
About Leap Therapeutics
Leap Therapeutics (NASDAQ: LPTX) is focused on developing
targeted and immuno-oncology therapeutics. Leap's most advanced
clinical candidate, DKN-01, is a humanized monoclonal antibody
targeting the Dickkopf-1 (DKK1)
protein, a Wnt pathway modulator. DKN-01 is in clinical trials in
patients with esophagogastric, hepatobiliary, gynecologic, and
prostate cancers. Leap's second clinical candidate, TRX518, is a
humanized GITR agonist monoclonal antibody designed to enhance the
immune system's anti-tumor response that is in advanced solid tumor
studies. For more information about Leap Therapeutics, visit
http://www.leaptx.com or our public filings with the SEC that are
available via EDGAR at http://www.sec.gov or via
https://investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include statements regarding Leap's
expectations with respect to the development and advancement of
DKN-01 and TRX518, including the initiation, timing and design of
future studies, enrollment in future studies, business development,
and other future expectations, plans and prospects. Although Leap
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from our expectations. Such risks and uncertainties
include, but are not limited to: the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs
for financing; the ability to complete a financing or form business
development relationships to fund our expenses; the outcome, cost,
and timing of our product development activities and clinical
trials; the uncertain clinical development process, including the
risk that clinical trials may not have an effective design or
generate positive results; our ability to obtain and maintain
regulatory approval of our drug product candidates; our plans to
research, develop, and commercialize our drug product candidates;
our ability to achieve market acceptance of our drug product
candidates; unanticipated costs or delays in research, development,
and commercialization efforts; the applicability of clinical study
results to actual outcomes; the size and growth potential of the
markets for our drug product candidates; our ability to continue
obtaining and maintaining intellectual property protection for our
drug product candidates; and other risks. Detailed information
regarding factors that may cause actual results to differ
materially will be included in Leap Therapeutics' periodic filings
with the SEC, including Leap's Annual Report on Form 10-K for the
fiscal year ended December 31, 2018,
as filed with the SEC on April 1,
2019 and Quarterly Report on Form 10-Q for the quarter ended
March 31, 2019, as filed with the SEC
on May 15, 2019. Any
forward-looking statements contained in this release speak only as
of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Argot Partners
Investor Relations
Heather Savelle
212-600-1902
heather@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-host-conference-call-to-provide-dkn-01-program-update-300889950.html
SOURCE Leap Therapeutics, Inc.